西藏多瑞医药股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人王运国，作为西藏多瑞医药股份有限公司（以下简称"公司"） 董事会的独立董事，本人 2024 年度严格按照《公司法》《深圳证券交 易所创业板股票上市规则》及其他有关法律法规和《公司章程》《独 立董事工作制度》等公司相关的规定和要求，在 2024 年度工作中， 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会、 董事会专门委员会、独立董事专门会议各项议案，对公司重大事项发 表意见，充分发挥了独立董事的作用，维护公司和公众股东的合法权 益，促进公司规范运作。现就本人 2024 年度履行独立董事职责情况 汇报如下： 一、独立性情况说明 2024 年度，本人未在公司担任除独立董事以外的任何职务，也 未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利 害关系或其他可能妨碍本人进行独立客观判断的关系，不存在其他影 响独立董事独立性的情况。 二、参加会议情况 （一）出席公司董事会及股东大会的情况 2024 年度，本着勤勉尽责的态度，本人积极参加公司召开的股 东大会、董事会，认真审阅会议材料，积极参与各议题的讨论并提出 ...

西藏多瑞医药股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人祁飞，作为西藏多瑞医药股份有限公司（以下简称"公司"） 董事会的独立董事，本人 2024 年度严格按照《公司法》《深圳证券交 易所创业板股票上市规则》及其他有关法律法规和《公司章程》《独 立董事工作制度》等公司相关的规定和要求，在 2024 年度工作中， 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会、 董事会专门委员会、独立董事专门会议各项议案，对公司重大事项发 表意见，充分发挥了独立董事的作用，维护公司和公众股东的合法权 益，促进公司规范运作。现就本人 2024 年度履行独立董事职责情况 汇报如下： 一、独立性情况说明 2024 年度，本人未在公司担任除独立董事以外的任何职务，也 未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利 害关系或其他可能妨碍本人进行独立客观判断的关系，不存在其他影 响独立董事独立性的情况。 二、参加会议情况 （一）出席公司董事会及股东大会的情况 2024 年度，本着勤勉尽责的态度，本人积极参加公司召开的股 东大会、董事会，认真审阅会议材料，积极参与各议题的讨论并提出 合 ...

Financial Performance - In 2024, the company's operating revenue was 240.6281 million yuan, a decrease of 28.02% compared to the same period last year[3]. - The net profit attributable to the parent company was -62.6667 million yuan, a decline of 432.44% year-on-year[3]. - The significant drop in performance was mainly due to factors such as drug price linkage, increased R&D expenses for new traditional Chinese medicine, and high initial production costs for some intermediate products[3]. - The gross profit margin was negative due to inventory write-downs and high production costs[3]. - The net cash flow from operating activities for 2024 was -¥67,177,874.47, a significant drop of 641.19% compared to ¥12,413,094.53 in 2023[25]. - The total net assets attributable to shareholders at the end of 2024 were ¥676,730,670.15, a decrease of 12.35% from ¥772,064,892.00 at the end of 2023[25]. - The company reported a quarterly revenue of ¥40,107,956.80 in Q4 2024, down from ¥78,457,398.26 in Q1 2024[27]. - The net profit attributable to shareholders in Q4 2024 was -¥45,587,927.01, worsening from -¥2,537,276.14 in Q1 2024[27]. - The company achieved operating revenue of 240.63 million yuan in 2024, a decrease of 28.02% compared to the previous year[44]. - The revenue from intermediates increased significantly, accounting for 15.79% of total revenue, up 927.66% year-on-year[46]. Research and Development - R&D investment accounted for 15.38% of operating income, showing a steady upward trend[43]. - The company has obtained 23 drug approval numbers by the end of the reporting period, with a dedicated R&D team of 75 members[43]. - The company’s R&D model combines independent and collaborative efforts with CROs to advance its pipeline projects[40]. - The company is actively pursuing vertical integration strategies to enhance its market position and expand into high-end peptide raw materials[39]. - The company is focusing on the transformation towards high-end peptide raw materials, with new products like Aiboweitai raw materials and levofloxacin sodium chloride injection in the pipeline[44]. - The company is actively developing traditional Chinese medicine products, including classic formulas and new drugs, to align with national policies promoting traditional medicine[86]. Market Position and Strategy - The company operates in a thriving industry without major risks related to overcapacity or technological obsolescence[4]. - The global peptide drug market is projected to grow at a CAGR of 8.9% from 2020 to 2025, with the Chinese market expected to grow at 16.4% during the same period, reaching $18.2 billion by 2025[36]. - The company has a market share of over 80% for its sodium acetate Ringer's injection product, which was included in the 10th batch of the national centralized drug procurement directory[39]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting firms with complementary technologies[114]. - The company plans to maintain a dividend payout ratio of 40% in the upcoming fiscal year, reflecting strong cash flow management[114]. Governance and Management - The company maintains independence from its controlling shareholders in business, personnel, assets, institutions, and finance[96]. - The company has established a complete procurement, production, and sales system, ensuring independent operational capabilities[96]. - The company has a robust financial management system with independent accounting professionals managing financial records[97]. - The company has a complete human resources management system, ensuring independence in personnel management[96]. - The board of directors includes independent members with diverse expertise, ensuring robust governance and oversight[106]. - The company has implemented a performance evaluation and incentive system linking management compensation to business performance, ensuring transparency in the hiring of senior management[94]. Environmental Responsibility - The company strictly adheres to various environmental protection laws and regulations during its operations[150]. - The company has implemented comprehensive waste treatment facilities to minimize environmental impact[151]. - The company has adopted a green, low-carbon, and high-quality sustainable development approach, focusing on energy-saving and carbon reduction throughout the product design and manufacturing processes[155]. - The company has invested CNY 4.2045 million in environmental governance and protection during the reporting period, while Sichuan Duorui, which has not yet commenced production, spent CNY 0.3986 million[154]. - The company has implemented a comprehensive environmental self-monitoring plan, with all monitoring data publicly disclosed on national and local pollution source monitoring platforms[153]. Financial Management and Compliance - The company has committed to fulfilling its obligations regarding employee social insurance and housing fund contributions, ensuring compliance with labor laws[179]. - The company has not reported any significant discrepancies in its governance compared to regulations set by the China Securities Regulatory Commission[95]. - The company has maintained compliance with information disclosure obligations, ensuring timely, accurate, and complete communication with investors[157]. - The company has committed to avoiding any business activities that may compete with its main operations, ensuring no conflicts of interest arise[175]. - The company guarantees that any commercial opportunities will be directed to its main business to prevent potential competition[176]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[110]. - The company plans to enhance employee training in 2024, focusing on skills development and high-level talent cultivation[131]. - The company plans to continue its market expansion and product development efforts in the coming year[44]. - The company is focused on maintaining transparency and accountability in its financial reporting[170].

Investment Rating - The report maintains a "Hold" rating for the healthcare sector [8] Core Viewpoints - The pharmaceutical sector slightly underperformed the CSI 300 index, with a decline of 5.61% from April 7 to April 11, 2025, ranking 22nd among 31 sectors [3][13] - Year-to-date, the pharmaceutical index has decreased by 1.10%, outperforming the CSI 300 index by 3.59 percentage points, ranking 13th among 31 sectors [15] - As of April 11, 2025, the valuation of the pharmaceutical sector stands at 25.91 times (TTM overall method, excluding negative values), with a premium of 141.73% compared to the CSI 300 index [18] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 7 to April 11, 2025, shows a decline of 5.61%, underperforming the CSI 300 index by 2.74 percentage points [3][13] - The valuation level of the pharmaceutical sector is reported at 25.91 times, with a significant premium over the CSI 300 index [18] - Top-performing stocks include Yirui Technology (+20.54%), Yipinhong (+17.03%), and Yong'an Pharmaceutical (+13.93%) [19][20] 2. Important Policies and Events - On April 7, 2025, the Ministry of Commerce and the National Health Commission, along with 12 other departments, issued the "Special Action Plan for Promoting Healthy Consumption" to enhance the quality of health goods and services [5][22] 3. Important Company Announcements - Haizike reported a revenue of 3.721 billion yuan for 2024, a year-on-year increase of 10.92%, with a net profit of 395 million yuan, up 34.00% [23] - Kexing Pharmaceutical announced a revenue of 1.407 billion yuan for 2024, with a net profit of 31 million yuan, marking a return to profitability [23] 4. Industry Perspectives - The report discusses the impact of the ongoing trade war, noting that while pharmaceuticals were initially included in tariff discussions, they were later excluded from the "reciprocal tariffs" announced by the U.S. government [6][25] - The report highlights that increased tariffs on imports from the U.S. could benefit domestic substitutes in the blood products, high-end medical devices, and innovative drug sectors [6][26]

西藏多瑞医药股份有限公司 关于控股股东质押部分股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）近日收到公司控 股股东西藏嘉康时代科技发展有限公司（以下简称"西藏嘉康"）通知， 获悉西藏嘉康所持有本公司的部分股权被质押，具体事项公告如下： 一、股份质押的基本情况 证券代码：301075 证券简称：多瑞医药 公告编号：2025-025 （二）股东股份累计被质押的情况 股东 姓名 是否为第一 大股东及其 一致行动人 本次质押 数量 （股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否为 补充质 押 质押起始 日 质押到期 日 质权人 质押 用途 西藏 嘉康 是 1,430,000 3.06% 1.79% 否 否 2025/4/10 质权人解 除质押登 记之日 浙江银通典 当有限责任 公司 担保 融资 合计 - 1,430,000 3.06% 1.79% - - - - - - （一）股东股份质押基本情况 截至公告披露日，上述股东所持质押股份情况如下： 股东 名称 持股数量 持股比例 本次质 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-024 注：上述金额未扣除交易费用，下同。 二、 关联关系说明 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。在额 度范围内授权公司法定代表人及其授权人士签署相关合同文件，授权 期限自董事会审议通过之日起 12 个月内有效。该事项已经公司董事 会、监事会审议通过，保荐机构中信证券股份有限公司对公司使用部 分暂时闲置募集资金进行现金管理出具了明确的核查意见。具体内容 详见于 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [35]. Core Insights - The pharmaceutical and biotechnology sector showed a 1.20% increase in performance from March 31 to April 3, ranking third among 31 industries and outperforming the CSI 300 index by 2.57 percentage points [11][16]. - Year-to-date, the sector has risen by 4.77%, ranking seventh among 31 industries and surpassing the CSI 300 index by 6.64 percentage points [16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.2 times, which is at a historically low level, with a 130% premium compared to the CSI 300 index [20]. Market Performance - The top three sub-sectors in terms of growth last week were chemical pharmaceuticals (3.45%), traditional Chinese medicine II (1.53%), and pharmaceutical commerce (1.48%) [11]. - A total of 344 stocks (72.57% of the sector) experienced price increases last week, with the top five performers being Duorui Pharmaceutical (56.32%), Weisi Medical (31.80%), Hasanlian (31.15%), Rundu Co. (27.01%), and Shengnuo Biological (21.54%) [25][26]. Industry News - On April 4, the Ministry of Commerce announced investigations into the competitiveness of imported medical CT tubes and initiated anti-dumping investigations against imports from the United States and India [27][30]. - The investigations will assess the impact of these imports on the domestic industry and its competitiveness, covering the period from January 1, 2024, to December 31, 2024, for dumping and from January 1, 2022, to December 31, 2024, for industry damage [29][30]. Investment Recommendations - The report suggests focusing on sectors such as innovative drugs, medical services, and domestic market-oriented businesses, which are less affected by trade frictions [31]. - It highlights the potential for accelerated domestic substitution in high-end medical equipment and blood products due to ongoing tariff disputes [31]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Boya Biological, with additional stocks to watch being Tebao Biological, Kelun Pharmaceutical, International Medicine, Kaili Medical, and Nuotai Biological [32].

证券代码：301075 证券简称：多瑞医药 公告编号：2025-023 西藏多瑞医药股份有限公司 关于股价异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 （四）公司、控股股东及实际控制人、持有 5%以上股份的股东 不存在关于公司的应披露而未披露的重大事项，或处于筹划阶段的重 大事项。 （五）股票异常波动期间，不存在控股股东、实际控制人买卖公 司股票的行为。 （六）公司不存在违反公平信息披露规定的情形。 西藏多瑞医药股份有限公司（以下简称"公司"或"多瑞医药"）股 票于 2025 年 3 月 28 日、2025 年 3 月 31 日、2025 年 4 月 1 日连续三 个交易日收盘价格涨幅偏离值累计超过 30%，根据深圳证券交易所相 关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票异常波动情况，公司董事会对有关事项进行了核实， 现就相关情况说明如下： （一）公司前期披露的信息不存在需要更正、补充之处。 （二）公司未发现近期公共传媒报道了可能或已经对公司股票交 易价格产生较大影响的未公开重大 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-022 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。在额 度范围内授权公司法定代表人及其授权人士签署相关合同文件，授权 期限自董事会审议通过之日起 12 个月内有效。该事项已经公司董事 会、监事会审议通过，保荐机构中信证券股份有限公司对公司使用部 分暂时闲置募集资金进行现金管理出具了明确的核查意见。具体内容 详见于巨潮资讯网（www.cninfo ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-021 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 | 序 | 购买 | 受托方名 | 产品名称 | 金额 （万 | 产品 | 产品起 | 产品 | 预期年化 | 赎回本 金（万 | 投资收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | 称 | | | 类型 | 息日 | 到期日 | 收益率 | | （元） | | | | | | 元） | | | | | 元） | | | 1 | 西藏多瑞 医药股份 | 招商证券 | 招商证券收益凭 | | 本金 | 2024/9/2 | 2025/3/2 | 1.5000%- | | 108,493.15 | | | | 股份有限 | 证-"搏金"255 | 1,100 | 保障 | | | | 1,100 | | | | | | | | ...